FDA Requests Minor Labeling Changes for NRx’s Preservative-Free Ketamine
Event summary
- FDA issued a Discipline Review Letter for NRx’s Preservative-Free Ketamine, requesting minor labeling changes.
- All requested changes classified as minor, with a November 10, 2026, GDUFA goal date for review completion.
- NRx is finalizing manufacturing Process Validation Runs to meet product launch requirements.
- Company aims to address domestic ketamine shortages with US-manufactured preservative-free formulation.
The big picture
NRx’s preservative-free ketamine addresses critical supply chain gaps in the US healthcare system, aligning with broader trends of reshoring pharmaceutical manufacturing. The FDA’s minor labeling requests suggest a smooth regulatory path, but execution risks remain in scaling production. Success could position NRx as a key player in neuroplastic therapies for depression and PTSD.
What we're watching
- Regulatory Approval
- Whether NRx can meet the November 10, 2026, GDUFA goal date for final FDA approval.
- Market Impact
- How successful US manufacturing of preservative-free ketamine will affect domestic supply shortages.
- Execution Risk
- The pace at which NRx completes final manufacturing validation runs for product launch.
Related topics
